Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.68, No.5, p.1043–1051, 2021 |
||
Title: HDAC3-mediated lncRNA-LOC101928316 contributes to cisplatin resistance in gastric cancer via activating the PI3K-Akt-mTOR pathway | ||
Author: Hengjie Ren, Liyun Tang | ||
Abstract: The present study aimed to explore how histone deacetylases (HDAC3) regulated the resistance to cisplatin by inhibiting the transcription of lncRNA-LOC101928316 (LOC101928316) in gastric cancer (GC). We revealed that HDAC3 expression in cisplatin-resistant cell lines was significantly higher than that of GC parental cell lines. Besides, knockdown of HDAC3 inhibited the cell activity, cell invasion, and migration but promoted the apoptosis of GC cisplatin-resistant cell lines. To our surprise, silencing HDAC3 inhibited the transcription of LOC101928316 by promoting the level of acetylation of H3K4 on the LOC101928316 promoter, thus promoting the LOC101 expression in GC cisplatin-resistant cell lines. Together, the overexpression of HDAC3 mediated LOC101928316 to promote GC resistance to cisplatin by activating the PI3K-Akt-mTOR pathway. Therefore, HDAC3 may serve as a potential target of cisplatin resistance in GC. |
||
Keywords: cisplatin resistance; gastric cancer; histone deacetylases 3; lncRNA-LOC101928316 | ||
Published online: 24-Aug-2021 | ||
Year: 2021, Volume: 68, Issue: 5 | Page From: 1043, Page To: 1051 | |
doi:10.4149/neo_2021_210317N356 |
||
|
download file |
|